直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
Jennifer H. Roscetti
Partner
More
vCard
  • 901 New York Avenue, NW
  • Washington, DC 20001-4413
+1 202 408 4150
jennifer.roscetti@finnegan.com jennifer.roscetti@finnegan.com

Jennifer H. Roscetti

Partner

  • +1 202 408 4150 +1 202 408 4150
  • jennifer.roscetti@finnegan.com jennifer.roscetti@finnegan.com
  • 901 New York Avenue, NW
  • Washington, DC 20001-4413
  • vCard

Jennifer Roscetti, co-leader of Finnegan’s litigation and trial section, focuses on patent litigation before U.S. district courts and the U.S. International Trade Commission (ITC). She also represents clients before the U.S. Court of Appeals for the Federal Circuit. Her practice encompasses a range of technologies primarily focused on chemical subject matter such as pharmaceuticals, cosmetics, and specialty chemicals. Jennifer was recognized by LMG Life Sciences as Hatch-Waxman Litigator of the Year, Branded.

Jennifer has particular experience in representing pharmaceutical patent holders in Abbreviated New Drug Application (ANDA) litigations for blockbuster pharmaceuticals. She has had key responsibilities in all aspects of federal district court litigations, from the initial pleading stage through discovery, motions, claim construction, and trial. She also provides strategic guidance to clients on infringement, validity and enforceability issues.

 

Jennifer’s proficiencies in the chemical area are supported by industry and research experience. Prior to her legal career, she worked as process design engineer for ExxonMobil Chemical Company and as a process engineer for E.I. du Pont de Nemours and Company in the Teflon® division. Jennifer also engaged in research on anti-cancer drugs in the College of Pharmacy at the University of Kentucky.

 

Jennifer regularly lectures in the United States and abroad concerning potential challenges and opportunities for the pharmaceutical and biotechnology industries in navigating recent developments in U.S. patent law. She serves as an adjunct professor in Patent Law and Advanced Topics in Patent Policy at Howard University of Law. Jennifer was shortlisted for the Life Sciences Lawyer of the Year at the 2023 Women in Business Law Awards, which recognizes leading women practitioners from over 30 practice areas.

 

Jennifer previously served as the leader of the firm's chemical and metallurgical practice group as well on the firm’s management committee.

 

Experience

Pronova Biopharma Norge AS v. Teva Pharmaceuticals USA, Inc.

Represented Pronova in Hatch-Waxman patent litigation concerning multiple ANDAs for generic versions of drug Lovaza®, resulting in judgment of patent infringement, validity, and enforceability in Pronova's favor.

1:09-cv-00286, 1:10-cv-00800, D. Del., Judges Farnan, Robinson, Thynge
12-1498, -1499, Fed. Cir., Judges Dyk, O'Malley, Wallach

Grünenthal GmbH v. Teva Pharmaceuticals

Represented Grünenthal GmbH in Hatch-Waxman litigations against several defendants relating to abuse-deterrent formulations of Opana®.

1:12-cv-08060, S.D.N.Y., Judges Griesa, Daniels, Gorenstein

Ariad Pharmaceuticals v. Eli Lilly and Company

Assisted in representing Eli Lilly  in district court and Federal Circuit in action to prevent generic competition with respect to osteoporosis drug Evista®. Two of three patent families in suit found valid and infringed.

08-1248, Fed. Cir., Judges Michel, Newman, Mayer, Lourie, Rader, Bryson, Gajarsa, Linn, Dyk, Prost, Moore
1:02-cv-11280, D. Mass., Judge Zobel

Rocket Pharmaceuticals, Inc. v. Beard et al.

Represented Rocket Pharmaceuticals, Inc. in district court litigation involving claims of trade secret misappropriation and breach of contract against corporate and individual defendants relating to complex treatments for genetic disorders. Obtained successful outcome including permanent injunction and other remedies against all defendants.

3:24-cv-02170, D. Or., Judge Simon

AbbVie Inc., et al. v. Aurobindo Pharma U.S.A., Inc. et al.

Finnegan is representing AbbVie, Allergan, and Merck in ongoing ANDA litigation involving Ubrelvy®, indicated for the acute treatment of migraine with or without aura in adults.

3:24-cv-04603, D.N.J., Judges Quraishi, Day
3:24-cv-04662, D.N.J., Judges Quraishi, Day
3:24-cv-04852, D.N.J., Judges Quraishi, Day

Rocket Pharmaceuticals, Inc. v. Lexeo Therapeutics, Inc., et al.

Represented Rocket Pharmaceuticals, Inc. in district court litigation involving claims of trade secret misappropriation and breach of contract against individual and corporate defendants and relating to complex treatments for genetic disorders. Successfully opposed motion to dismiss key claims and obtained settlement with all defendants following completion of fact discovery.

1:23-cv-09000, S.D.N.Y., Judges Castel, Aaron

More

Insights

Conference

IP Forum for Life Sciences 2025 IP Forum for Life Sciences 2025

December 3-5, 2025

Coral Gables

Conference

IP Forum for Life Sciences 2024 IP Forum for Life Sciences 2024

December 4-6, 2024

Coral Gables

Conference

IP Forum for Life Sciences IP Forum for Life Sciences

December 4-6, 2023

Westlake Village

Webinar

How and Why to Litigate Before the Unified Patent Court

How and Why to Litigate Before the Unified Patent Court How and Why to Litigate Before the Unified Patent Court

October 19, 2022

Webinar

Webinar

Managing Global Patent & Trademark Litigation

Managing Global Patent & Trademark Litigation Managing Global Patent & Trademark Litigation

June 16, 2021

Webinar

Conference

Energy IP Summit 2020 Energy IP Summit 2020

December 10, 2020

Virtual

More

News

Commentary

Litigation Leaders: Finnegan’s Jennifer Roscetti on the Advantages of Being Fully Focused on IP Litigation Leaders: Finnegan’s Jennifer Roscetti on the Advantages of Being Fully Focused on IP

April 6, 2026

The AmLaw Litigation Daily

Press Release

Finnegan Recognized as a Leading Firm in the 2025 LMG Life Sciences Americas Rankings Finnegan Recognized as a Leading Firm in the 2025 LMG Life Sciences Americas Rankings

October 1, 2025

LMG Life Sciences

Award/Ranking

Finnegan Remains a Tier 1 Firm in the 2024 LMG Life Sciences Rankings Finnegan Remains a Tier 1 Firm in the 2024 LMG Life Sciences Rankings

October 4, 2024

LMG Life Sciences

Award/Ranking

Finnegan Wins Big at the 2024 LMG Life Sciences Americas Awards Finnegan Wins Big at the 2024 LMG Life Sciences Americas Awards

September 6, 2024

LMG Life Sciences

Award/Ranking

Finnegan Shortlisted for 14 LMG Life Sciences 2024 Americas Awards Finnegan Shortlisted for 14 LMG Life Sciences 2024 Americas Awards

July 18, 2024

LMG Life Sciences

Award/Ranking

Finnegan Shortlisted for the Women in Business Law Awards Americas 2023 Finnegan Shortlisted for the Women in Business Law Awards Americas 2023

April 6, 2023

Women in Business Law
More

Professional Activities

  • American Bar Association
  • American Institute of Chemical Engineers
    (AIChE program vice-chair, Chemical Engineering and the Law Forum, 2015)
  • American Intellectual Property Law Association
  • ITC Trial Lawyers Association
  • Maryland State Bar
  • Women's Bar Association of the District of Columbia
Admissions and Education

Admissions

  • U.S. Patent and Trademark Office
  • District of Columbia
  • Maryland
  • U.S. Court of Appeals, Federal Circuit

Education

University of Houston Law Center
J.D., 2005
University of Kentucky
B.S., Chemical Engineering, cum laude, 2002

Jennifer's Practices

Global IP Enforcement, Litigation, and Trials
Branded Hatch-Waxman (ANDA) Litigation and Trials
ITC Section 337 Investigations and Trials
Patent Litigation and Trials
Trade Secrets
Prosecution and Portfolio Management
Patent Drafting and Prosecution
Trade Secrets

Jennifer's Industries

Chemicals, Industrials, and Materials
Chemical
Energy
Oil and Gas
Life Sciences
Biologics
Pharmaceutical

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP